1 / 14

Aarkstore -Interleukin-23 (IL-23) Inhibitors -Pipeline Insig

Interleukin-23 (IL-23) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA).

addyparker2350
Download Presentation

Aarkstore -Interleukin-23 (IL-23) Inhibitors -Pipeline Insig

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals & Healthcare Interleukin-23 (IL-23) Inhibitors -Pipeline Insights, 2014 Browse Complete Report - http://www.aarkstore.com/pharmaceuticals-healthcare/75781/interleukin-23-il-23-inhibitors-pipeline-insights-2014

  2. Summary DelveInsights,Interleukin-23 (IL-23) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Interleukin-23 (IL-23) Inhibitors. This report provides information on the therapeutic development based on the Interleukin-23 (IL-23) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

  3. Summary Data Sources The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action. 

  4. Summary Scope  The report provides a snapshot of the global therapeutic landscape of Interleukin-23 (IL-23) InhibitorsThe report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical informationCoverage of the Interleukin-23 (IL-23) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule typeThe report reviews key players involved in the therapeutics development for Interleukin-23 (IL-23) Inhibitors and also provide company profilingThe report also gives the information of dormant and discontinued pipeline projects Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

  5. Summary Reasons to buyComplete MOA intelligence and complete understanding over therapeutics development for Interleukin-23 (IL-23) Inhibitors Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine. Devise corrective measures for pipeline projects by understanding Interleukin-23 (IL-23) Inhibitors pipeline depth and focus of Indication therapeutics Developing strategic initiatives to support your drug development activities. Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

  6. Summary Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

  7. Table of Content Interleukin-23 (IL-23) Inhibitors Overview Interleukin-23 (IL-23) Inhibitors Disease Associated Interleukin-23 (IL-23) Inhibitors Pipeline Therapeutics Interleukin-23 (IL-23) Inhibitors Therapeutics under Development by Companies Interleukin-23 (IL-23) Inhibitors Late Stage Products (Filed and Phase III) Comparative Analysis Interleukin-23 (IL-23) Inhibitors Mid Clinical Stage Products (Phase II) Comparative Analysis Interleukin-23 (IL-23) Inhibitors Early Clinical Stage Products (Phase I and IND Filed) Comparative Analysis Interleukin-23 (IL-23) Inhibitors Discovery and Pre-Clinical Stage Products Comparative Analysis Drug Candidate Profiles

  8. Table of Content Interleukin-23 (IL-23) Inhibitors Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Interleukin-23 (IL-23) Inhibitors Discontinued Products Interleukin-23 (IL-23) Inhibitors Dormant Products Companies Involved in Therapeutics Development for Interleukin-23 (IL-23) Inhibitors Appendix Methodology Contact Us Disclaimer

  9. List of Tables Number of Products under Development for Interleukin-23 (IL-23) Inhibitors by Therapy Area, 2014 Number of Products under Development for Interleukin-23 (IL-23) Inhibitors, 2014 Number of Products under Development by Companies Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014 Comparative Analysis Mid Clinical Stage Products (Phase II), 2014 Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014 Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014 Drug Candidates Profiles Interleukin-23 (IL-23) Inhibitors Assessment by Monotherapy Products

  10. List of Tables Interleukin-23 (IL-23) Inhibitors Assessment by Combination Products Interleukin-23 (IL-23) Inhibitors Assessment by Route of Administration Interleukin-23 (IL-23) Inhibitors Assessment by Stage and Route of Administration Interleukin-23 (IL-23) Inhibitors Assessment by Molecule Type Interleukin-23 (IL-23) Inhibitors Assessment by Stage and Molecule Type Interleukin-23 (IL-23) Inhibitors Therapeutics Discontinued Products Interleukin-23 (IL-23) Inhibitors Therapeutics Dormant Products Products under Development by Companies, 2014

  11. List of Figures Number of Products under Development for Interleukin-23 (IL-23) Inhibitors by Therapy Area, 2014 Number of Products under Development for Interleukin-23 (IL-23) Inhibitors, 2014 Late Clinical Stage Products (Filed and Phase III), 2014 Mid Clinical Stage Products (Phase II), 2014 Early Clinical Stage Products (Phase I and IND Filed), 2014 Discovery and Pre-Clinical Stage Products, 2014 Interleukin-23 (IL-23) Inhibitors Assessment by Monotherapy Products Interleukin-23 (IL-23) Inhibitors Assessment by Combination Products Interleukin-23 (IL-23) Inhibitors Assessment by Route of Administration Interleukin-23 (IL-23) Inhibitors Assessment by Stage and Route of Administration Interleukin-23 (IL-23) Inhibitors Assessment by Molecule Type Interleukin-23 (IL-23) Inhibitors Assessment by Stage and Molecule Type

  12. Related Reports • 2015 Worldwide Medical Laboratories Industry-Industry & Market Report • 2015 Worldwide Pharmaceutical Preparation Mfg. Industry-Industry & Market Report • OncoPlex Diagnostics - Pharmaceuticals & Healthcare - Deals and Alliances Profile • MetaStat, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile • Advanced Cell Diagnostics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile • Ascension Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile • Accretive Health, Inc. (ACHI) - Strategic SWOT Analysis Review • Jazz Pharmaceuticals plc (JAZZ) - Financial and Strategic SWOT Analysis Review • Pharmstandard (PHST) - Financial and Strategic SWOT Analysis Review • GLG Life Tech Corporation (GLG) - Financial and Strategic SWOT Analysis Review

  13. Interleukin-23 (IL-23) Inhibitors -Pipeline Insights, 2014 Published: Dec. 2014 | 60 Pages DelveInsights,Interleukin-23 (IL-23) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). Price

  14. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related